BioRestorative Therapies, Inc. (BRTX) Stock Score, Valuation & Financial Research
BioRestorative Therapies, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for BRTX
BioRestorative Therapies, Inc. currently has a Wall Street Score of 29/100. The stored market price is $2.64. Its financial score is 22/100. Its valuation score is 0/100. The latest WSS change is +0.5 points. These figures are a research snapshot, not a buy or sell recommendation.
What BioRestorative Therapies, Inc. does
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core
BRTX financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $2.64
- Market capitalization:
- $3.6M
- Revenue:
- $358K
- Net income:
- $-11.1M
- Free cash flow:
- $-10.9M
- Cash:
- $3.1M
- Total debt:
- $35K
- EPS:
- -22.20
- Financial score:
- 22/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-10.9M, showing cash burn in the current stored period.
- The balance sheet shows $3.1M of cash versus $35K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.5 points: BRTX increased 0.5 points because Asset improved by 5.9 points.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 22/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BRTX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.